Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Rectal Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1HER2-positive Gastric Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Capecitabine 13Oxaliplatin 10Radiotherapy 8Surgical Procedures, Operative 6Drug Therapy 5tislelizumab 4Irinotecan 4sintilimab 3Neoadjuvant Therapy 3Immunotherapy 3Fluorouracil 3Endoscopic Mucosal Resection 3Bevacizumab 3spartalizumab 2raltitrexed 2XELOX 2Trinitrotoluene 2Radiation 2Immune Checkpoint Inhibitors 2Folfox protocol 2Cetuximab 2toripalimab 1sperm releasing substance 1saxagliptin 1s-formylglutathione hydrolase 1envafolimab 1disitamab vedotin 1cemiplimab 1camrelizumab 1balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Rectal Neoplasms × disitamab vedotin × Clear all
NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
29 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡